Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy

Nephrology Dialysis Transplantation

Volumn 19, Issue 11, 2004, Pages 2852-2857

  Artz, Marika A ^a   Hilbrands, Luuk B ^a   Borm, George ^a   Assmann, Karel J M ^a   Wetzels, Jack F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic allograft nephropathy; Prognosis; Renal transplantation; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN; VASODILATOR AGENT;

ADULT; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; FEMALE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HYPERKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; KIDNEY TUBULE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TIME;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CREATININE; DISEASE PROGRESSION; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 8344234197     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh462     Document Type: Article

References (20)

1. Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 2001; 38: S44-S50
2. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573
3. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217-222
4. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme-inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
6. Smit-van Oosten A, Navis G, Stegeman CA et al. Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J Pathol 2001; 194: 122-129
7. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58-63
8. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723
9. Lin J, Valeri AM, Markowitz GS et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73: 783-788
10. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648-654
11. Praga M, Hernandez E, Montoyo C et al. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992; 20: 240-248
12. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583
13. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000; 35: 1155-1165
14. Jorgensen E, Kelbaek H, Helqvist S et al. Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001; 38: 1434-1439
15. Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ et al. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 2001; 357: 33-37
16. Campistol JM, Inigo P, Jimenez W et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714-719
17. Lahlou A, Peraldi MN, Thervet E et al. Chronic graft dysfunction in renal transplant patients: potential role of plasminogen activator inhibitor type 1. Transplantation 2002; 73: 1290-1295
18. Wilensky RL. Angiotensin-receptor blockers: revival of the systemic prevention of restenosis? Cardiovasc Drugs Ther 17, 63-73. 2003
19. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002; 40: 859-865
20. Laverman GD, Remuzzi G, Ruggenenti P. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol 2004; 15 [Suppl 1]: S64-S70